What is Anika Therapeutics's PP&E (net)?

Anika Therapeutics (ANIK) reported PP&E (net) of $39.72M in Q1 2026.

How has Anika Therapeutics's PP&E (net) changed year-over-year?

Anika Therapeutics's PP&E (net) decreased by 1.8% year-over-year, from $40.46M to $39.72M.

What is the long-term trend for Anika Therapeutics's PP&E (net)?

Over 5 years (2020 to 2025), Anika Therapeutics's PP&E (net) has grown at a -4.4% compound annual growth rate (CAGR), from $50.61M to $40.32M.

What does PP&E (net) mean?

Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Anika Therapeutics ANIK PP&E (Net)

PP&E (Net) at other companies

StrykerSYK

$3.89B+9.9%

VericelVCEL

$107.11M-1.1%

Zimmer Biomet HoldingsZBH

$2.21B+7.1%

Pacira BioSciences, Inc.PCRX

$136.28M-17.1%

BioventusBVS

$21.29M-17.2%

Xtant Medical HoldingsXTNT

$5.85M-45.4%

Segments

By geography

See full

US$37.96M—

IT$1M—

GB$29K—

Other financials

Income statement

See full

Revenue$29.6M+13.2%

Net income-$5.1M-3.8%

Balance sheet

See full

Cash & equivalents$41.0M-23.1%

Total debt$25.7M+1.2%

Total equity$133.9M-9.8%

Total assets$179.4M-5.9%

Cash flow

See full

Operating cash flow-$4.8M-3,628%

CapEx$1.4M-49.3%

Free cash flow-$6.3M-112%

Valuation

See full

Market cap$204.37M+31.6%

Enterprise value$189.09M+48.7%

P/S1.8×+0.1×

Profitability

See full

Net margin-9.8%-4.4pp

FCF margin0.9%—

Returns & leverage

See full

Return on equity-8%-3.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Anika Therapeutics's PP&E (net)?: Anika Therapeutics (ANIK) reported PP&E (net) of $39.72M in Q1 2026.
How has Anika Therapeutics's PP&E (net) changed year-over-year?: Anika Therapeutics's PP&E (net) decreased by 1.8% year-over-year, from $40.46M to $39.72M.
What is the long-term trend for Anika Therapeutics's PP&E (net)?: Over 5 years (2020 to 2025), Anika Therapeutics's PP&E (net) has grown at a -4.4% compound annual growth rate (CAGR), from $50.61M to $40.32M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.